United States patent law

STMicroelectronics releases long-range wireless microcontrollers for energy-efficient connectivity in smart metering, smart building, and industrial monitoring

Retrieved on: 
Monday, November 20, 2023

Device and application designers can leverage ST’s wireless MCUs to develop and deliver new products to the world quickly for maximum benefit.

Key Points: 
  • Device and application designers can leverage ST’s wireless MCUs to develop and deliver new products to the world quickly for maximum benefit.
  • For example, Lierda Internet of Things Technology, is using the STM32WL33 to reduce power and add long range wireless connectivity to existing networking products.
  • Another customer, Silent Smart Technology, has created a family of modules based on STM32WL3 wireless MCUs that operate in various sub-1GHz frequency bands.
  • STM32 is a registered and/or unregistered trademark of STMicroelectronics International NV or its affiliates in the EU and/or elsewhere.

Dragonfly Energy Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Monday, November 13, 2023

As expected, this had a material adverse impact on our OEM sales in the third quarter of 2023.

Key Points: 
  • As expected, this had a material adverse impact on our OEM sales in the third quarter of 2023.
  • Third quarter 2023 Gross Profit was $4.6 million, compared to $7.0 million in the third quarter of 2022.
  • Third quarter 2023 EBITDA was $(5.7) million, compared to EBITDA of $(3.1) million in the third quarter of 2022.
  • Dragonfly Energy retains strong financial flexibility with access to a largely undrawn $150 million equity line of credit.

RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs

Retrieved on: 
Thursday, November 9, 2023

PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.

Key Points: 
  • PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.
  • There are two forms of the disease; wet AMD and dry AMD.
  • ADI estimates there are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds.
  • The Company’s novel approach includes the use of high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs.

USPTO Issues Final Rejection of Magnolia Medical’s ‘483 Patent at Issue in Litigation

Retrieved on: 
Wednesday, December 6, 2023

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the US Patent and Trademark Office has issued a Final Rejection in its reexamination of claims 1 and 24 of U.S. Patent No.

Key Points: 
  • Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced today that the US Patent and Trademark Office has issued a Final Rejection in its reexamination of claims 1 and 24 of U.S. Patent No.
  • 10,039,483 (the ‘483 patent).
  • Claims 1 and 24 of the ‘483 patent were asserted by Magnolia Medical against Kurin’s Lock product in a patent infringement case in Delaware Federal Court.
  • The USPTO Examiner has rejected Magnolia’s arguments regarding patentability, and the pertinent claims of that patent now stand as rejected.

Hayden AI Granted Patent for Traffic Violation Evidence Review System

Retrieved on: 
Thursday, November 30, 2023

Hayden AI, a global leader in artificial intelligence and geospatial analytics, has been awarded a patent for its system for automatically validating video evidence of traffic violations, enabling cities to enforce dangerous traffic violations at scale.

Key Points: 
  • Hayden AI, a global leader in artificial intelligence and geospatial analytics, has been awarded a patent for its system for automatically validating video evidence of traffic violations, enabling cities to enforce dangerous traffic violations at scale.
  • The patent was awarded on October 3, 2023 and is labeled US Patent number 11,776,276, B1.
  • Hayden AI’s mobile perception platform utilizes computer vision and deep learning technology that automatically detects context features to determine if a traffic violation occurred in video evidence.
  • By inputting video frames of a potential traffic violation into a deep learning algorithm, Hayden AI’s solution “scores” each evidence package to identify difficult cases.

Mitel Appoints Luiz Domingos as Chief Technology Officer

Retrieved on: 
Wednesday, November 29, 2023

Mitel® , a global leader in business communications, today announced that Luiz Domingos has been named Chief Technology Officer (CTO) and Head of Large Enterprise R&D.

Key Points: 
  • Mitel® , a global leader in business communications, today announced that Luiz Domingos has been named Chief Technology Officer (CTO) and Head of Large Enterprise R&D.
  • View the full release here: https://www.businesswire.com/news/home/20231129568175/en/
    Luiz Domingos, Chief Technology Officer (CTO) and Head of Large Enterprise R&D at Mitel.
  • During his tenure at Unify, he served as Chief Product and Technology Officer, managing the complete portfolio and developing disruptive cloud solutions.
  • “I am thrilled and honored to take on this role, especially during such a significant time at Mitel," said Domingos.

Cobalt Iron Secures Patent on Applying Machine Learning to Cyber Inspection

Retrieved on: 
Thursday, November 16, 2023

Cobalt Iron Inc. today announced that it has received another new patent, this time for machine learning-driven cyber inspection.

Key Points: 
  • Cobalt Iron Inc. today announced that it has received another new patent, this time for machine learning-driven cyber inspection.
  • Automatic adjustment of policy-driven cyber inspection using multiple cyber inspection tools and multiple cyber inspection levels:
    at different times or events in the life cycle of a data object.
  • In another instance, the technology might enable Compass to analyze machine learning training data from previous cyber attacks and previous cyber inspection operations to determine whether a different cyber inspection tool or a different level of inspection would be more effective at detecting particular types of cyber attack patterns.
  • And if so, it may dynamically adjust the cyber inspection tool or level of inspection it performs against particular types of data in future cyber inspection operations.

HeartBeam Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023

“During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.

Key Points: 
  • “During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.
  • Research and development expenses for the third quarter of 2023 were $1.6 million, compared to $1.6 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $2.1 million compared to $2.0 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $3.5 million, compared to a net loss of $3.6 million for the third quarter of 2022.

Bioceres Crop Solutions Reports Fiscal First Quarter 2024 Financial and Operational Results

Retrieved on: 
Monday, November 13, 2023

Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the first quarter ended September 30, 2023.

Key Points: 
  • Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, announced financial results for the first quarter ended September 30, 2023.
  • Financial results are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards.
  • Total revenues in 1Q24 were $116.6 million, driven by post-drought recovery at the start of the Argentine summer crop season, and continued global expansion.
  • Mr. Federico Trucco, Bioceres’ Chief Executive Officer, commented: “The first quarter of fiscal 2023 was a record-setting quarter in which we nearly doubled revenues as compared to the prior year period.

MYOS CORP Announces Significant New Patent for Increasing Mobility and Activity in Dogs

Retrieved on: 
Tuesday, December 12, 2023

CEDAR KNOLLS, N.J., Dec. 12, 2023 /PRNewswire-PRWeb/ -- MYOS CORP, an innovation-driven medical nutrition company, announced today that it has been awarded US Patent No. 11,833,186, for its signature proprietary product, Fortetropin® - further cementing its science-backed claims to enhance mobility and activity in aging canines.

Key Points: 
  • CEDAR KNOLLS, N.J., Dec. 12, 2023 /PRNewswire-PRWeb/ -- MYOS CORP, an innovation-driven medical nutrition company, announced today that it has been awarded US Patent No.
  • 11,833,186, for its signature proprietary product, Fortetropin® - further cementing its science-backed claims to enhance mobility and activity in aging canines.
  • "We're gratified that the US Patent Office continues to recognize the distinctiveness and effectiveness of Fortetropin, granting us robust patent protection."
  • "MYOS stands out in protecting our innovative products with patents backed by clinically-validated, peer-reviewed studies," said MYOS CORP CEO Joe Mannello.